Vitti Long Haul is a life sciences company dedicated to advancing scientific research and exploring innovative approaches for people experiencing the long-term effects of COVID-19. The company focuses on investigational therapies for persistent Long COVID symptoms and related pulmonary conditions, including pulmonary fibrosis. Through ongoing clinical research and scientific development, it aims to contribute to a better understanding of these complex health challenges and explore potential therapeutic options.
A key area of research involves mesenchymal stem cells, exosomes, and biomaterials. These biological components are being investigated for their potential applications in medical science and regenerative research. The company’s investigational therapies, VL-PX10 and VL-P22, are developed using a proprietary combination of human umbilical cord mesenchymal stem cell exosomes, mesenchymal stem cells, and their biomaterials. These therapies are being studied in human clinical research to evaluate their safety and potential benefits.
Long COVID can involve persistent symptoms such as fatigue, shortness of breath, reduced exercise tolerance, and other ongoing health concerns. For some individuals, respiratory complications may significantly affect daily activities and quality of life. Pulmonary fibrosis, a condition associated with scarring of lung tissue, is another important area of medical investigation. Clinical trials help researchers collect scientific evidence, evaluate investigational treatments, and improve their understanding of potential approaches to these conditions.
Vitti Long Haul provides information about its clinical research programs to patients, caregivers, and healthcare professionals interested in learning more about investigational treatment options. Eligible individuals may explore available clinical trial opportunities, subject to the study’s inclusion and exclusion criteria. For certain patients who do not qualify for a clinical trial, a physician-led Expanded Access Program may also be an option, depending on eligibility and applicable regulatory requirements.
The company emphasizes scientific research, responsible clinical development, and communication with medical professionals. Its work reflects the continuing effort to investigate new approaches for people affected by persistent COVID-19 complications and related respiratory conditions. Patients and physicians can visit the official website to learn more about the research programs, investigational therapies, and relevant participation information.
Through its focus on Long COVID research, pulmonary fibrosis studies, mesenchymal stem cells, and exosome-based approaches, Vitti Long Haul remains committed to contributing to the ongoing scientific exploration of potential treatment options. Its website serves as a resource for individuals seeking information about clinical research and developments in this evolving field.

